title: Serum p53 antibody in breast cancer.
abstract: BACKGROUND
  The significance of the measurement of anti-p53 antibodies in serum remains undisclosed. The aim of this study was to assess anti-p53 antibodies in the serum of patients with breast cancer, and correlate these results with various clinicopathologic parameters.
  
  
  METHODS
  We analyzed serum anti-p53 antibody levels in 124 patients with breast cancers and 7 patients with benign disease between April 2012 and March 2013, as well as levels of serum carcinoembryonic antigen (CEA) and cancer antigen (CA) 15-3.
  
  
  RESULTS
  Twenty-two of 124 patients with breast cancer had an increased concentration of anti-p53 antibodies. By distribution of clinical stage, in stage 0-II the positive ratio of anti-p53 antibodies was significantly higher than that of CEA (p=0.03) and CA15-3 (p=0.01). There was a significant correlation between anti-p53 antibodies and family history (p=0.03). Triple-negative cancer also showed a significant correlation with anti-p53 antibodies (p=0.007). In patients with multiple and/or bilateral breast cancer, the level of anti-p53 was significantly higher than in unilateral breast cancer (62.5% vs 14.7%, p=0.004).
  
  
  CONCLUSIONS
  Measurement of anti-p53 antibodies is useful for the prevention of oversight in the evaluation of multiple and/or bilateral breast cancer.
authors.affiliation: Department of Breast Cancer, Yokohama Rousai Hospital, Kouhoku-ku, Yokohama-city, Japan.
authors.forename: Shinya
authors.initials: S
authors.lastname: Yamamoto
authors.affiliation: Department of Breast Cancer, Yokohama Rousai Hospital, Kouhoku-ku, Yokohama-city, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Chishima
authors.affiliation: Department of Breast Cancer, Yokohama Rousai Hospital, Kouhoku-ku, Yokohama-city, Japan.
authors.forename: Shouko
authors.initials: S
authors.lastname: Adachi
authors.affiliation: Department of Breast Cancer, Yokohama Rousai Hospital, Kouhoku-ku, Yokohama-city, Japan.
authors.forename: Fumi
authors.initials: F
authors.lastname: Harada
authors.affiliation: Department of Breast Cancer, Yokohama Rousai Hospital, Kouhoku-ku, Yokohama-city, Japan.
authors.forename: Youko
authors.initials: Y
authors.lastname: Toda
authors.affiliation: Department of Breast Cancer, Yokohama Rousai Hospital, Kouhoku-ku, Yokohama-city, Japan.
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Arioka
authors.affiliation: Department of Breast Cancer, Yokohama Rousai Hospital, Kouhoku-ku, Yokohama-city, Japan.
authors.forename: Naoki
authors.initials: N
authors.lastname: Hasegawa
authors.affiliation: Department of Breast Cancer, Yokohama Rousai Hospital, Kouhoku-ku, Yokohama-city, Japan.
authors.forename: Yukio
authors.initials: Y
authors.lastname: Kakuta
mesh_terms: D000912:Antibodies, Neoplasm / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood* / Q000276:immunology / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D016159:Tumor Suppressor Protein p53 / Q000276:immunology*
chemical_list: D000912:Antibodies, Neoplasm; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53
keywords: breast cancer; p53